Literature DB >> 3335117

Plasma concentration-response relationships for some cardiovascular effects of dihydropyridines in healthy subjects.

K H Graefe1, R Ziegler, W Wingender, K D Rämsch, H Schmitz.   

Abstract

The pharmacokinetics and some hemodynamic effects of three dihydropyridine (DHP) calcium channel blockers were studied in healthy subjects. In a randomized order, each subject was given 24 micrograms/kg nifedipine, 40 micrograms/kg nitrendipine, or 10 micrograms/kg nisoldipine intravenously. The three DHPs differed as to their total clearance and volume of distribution (nifedipine less than nisoldipine less than nitrendipine) but showed similar values for elimination half-lives. All three drugs evoked increases in heart rate and forearm blood flow (FBF) and small decreases in blood pressure. Whereas the observed peak changes in heart rate were virtually identical for the three drugs (about 45% above baseline), the peak changes in FBF were more pronounced in response to nitrendipine and nisoldipine (greater than 200% above baseline) than in response to nifedipine (79% above baseline). The heart rate and FBF responses to the DHPs were related directly to the drug concentrations in plasma. The plasma level-response curves obeyed Hill's equation. They showed that the DHPs differ mainly in their potencies at dilating the forearm resistance vessels (nifedipine less than nitrendipine less than nisoldipine).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3335117     DOI: 10.1038/clpt.1988.6

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

1.  Pharmacokinetic-pharmacodynamic model for fantofarone cardiac and brachial haemodynamic effects in healthy volunteers.

Authors:  E Bellissant; J F Giudicelli
Journal:  Br J Clin Pharmacol       Date:  1999-12       Impact factor: 4.335

2.  Vasodilatory effects of nisoldipine on coronary arteries--correlation with plasma levels.

Authors:  S Jost; W Rafflenbeul; B Mogwitz; D Gulba; H Hecker; P R Lichtlen
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

Review 3.  Clinical pharmacokinetics of calcium antagonists. An update.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

Review 4.  Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  H A Friedel; E M Sorkin
Journal:  Drugs       Date:  1988-12       Impact factor: 9.546

Review 5.  Concentration-effect analysis of antihypertensive drug response. Focus on calcium antagonists.

Authors:  R Donnelly; H L Elliott; P A Meredith
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

Review 6.  Influence of drug formulation on drug concentration-effect relationships.

Authors:  G Castañeda-Hernández; G Caillé; P du Souich
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

7.  Correlation between the plasma concentration of mepirodipine and its occupancy of Ca2+ antagonist receptors in rats.

Authors:  S Yamada; Y Matsuoka; R Kimura
Journal:  Pharm Res       Date:  1993-09       Impact factor: 4.200

8.  The receptor occupation and plasma concentration of NKY-722, a water-soluble dihydropyridine-type calcium antagonist, in spontaneously hypertensive rats.

Authors:  S Uchida; S Yamada; T Ohkura; M Heshikiri; A Yoshimi; H Shirahase; R Kimura
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

Review 9.  The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.

Authors:  J S Grundy; R T Foster
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

10.  Comparative effects of felodipine, nitrendipine and nifedipine in healthy subjects: concentration-effect relationships of racemic drugs and enantiomers.

Authors:  P A Soons; A F Cohen; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.